[
  {
    "ts": "2025-08-21T20:56:03+00:00",
    "headline": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
    "summary": "Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.",
    "url": "https://www.investors.com/news/technology/gilead-stock-hiv-prevention-yeztugo-cvs-health/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "09b0e250-b374-3cb6-92cf-3a1abd89dba9",
      "content": {
        "id": "09b0e250-b374-3cb6-92cf-3a1abd89dba9",
        "contentType": "STORY",
        "title": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
        "description": "",
        "summary": "Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.",
        "pubDate": "2025-08-21T20:56:03Z",
        "displayTime": "2025-08-21T20:56:03Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/09b0e250-b374-3cb6-92cf-3a1abd89dba9/gilead-topples-on-a-surprise.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3HS_v1sTXYEP8DTCYUYLJg--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I5EJ4LrwA0DL6x_L77OdSA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gilead-stock-hiv-prevention-yeztugo-cvs-health/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T20:04:57+00:00",
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Thursday afternoon with the NYSE Health Care Index adding 0.1% an",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-200457673.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "807a1f7b-1b47-345d-a42c-20d22ea72776",
      "content": {
        "id": "807a1f7b-1b47-345d-a42c-20d22ea72776",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Mixed Late Afternoon",
        "description": "",
        "summary": "Health care stocks were mixed late Thursday afternoon with the NYSE Health Care Index adding 0.1% an",
        "pubDate": "2025-08-21T20:04:57Z",
        "displayTime": "2025-08-21T20:04:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-200457673.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-mixed-200457673.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MODV"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "PTIX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T16:15:00+00:00",
    "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
    "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
    "url": "https://www.barrons.com/articles/gilead-insurers-cvs-hiv-yeztugo-79e758ef?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "a44d8a0d-a3b0-3675-9639-d606d28dcf6e",
      "content": {
        "id": "a44d8a0d-a3b0-3675-9639-d606d28dcf6e",
        "contentType": "STORY",
        "title": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
        "description": "",
        "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
        "pubDate": "2025-08-21T16:15:00Z",
        "displayTime": "2025-08-21T16:15:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a44d8a0d-a3b0-3675-9639-d606d28dcf6e/gilead-needs-insurers-to.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/14ef431bdc98cbc2850bab7ce5db1477",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EBfHFeZzDdcNplXDeGxTOA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/14ef431bdc98cbc2850bab7ce5db1477.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UIzLC8XCiFPKW96jwhzmwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/14ef431bdc98cbc2850bab7ce5db1477.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/gilead-insurers-cvs-hiv-yeztugo-79e758ef?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CI"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T15:16:01+00:00",
    "headline": "Why Gilead Sciences (GILD) Shares Are Sliding Today",
    "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.",
    "url": "https://finance.yahoo.com/news/why-gilead-sciences-gild-shares-151601752.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "019de4ed-e0b4-3d00-a914-f1228e2f0971",
      "content": {
        "id": "019de4ed-e0b4-3d00-a914-f1228e2f0971",
        "contentType": "STORY",
        "title": "Why Gilead Sciences (GILD) Shares Are Sliding Today",
        "description": "",
        "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.",
        "pubDate": "2025-08-21T15:16:01Z",
        "displayTime": "2025-08-21T15:16:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-gilead-sciences-gild-shares-151601752.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-gilead-sciences-gild-shares-151601752.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T15:12:22+00:00",
    "headline": "Coty, Gilead Sciences, Rent the Runway: Trending tickers",
    "summary": "Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead Sciences (GILD), and Rent the Runway (RENT). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finance.yahoo.com/video/coty-gilead-sciences-rent-runway-151222727.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "319e8988-341d-376c-97b5-d63f7c98c656",
      "content": {
        "id": "319e8988-341d-376c-97b5-d63f7c98c656",
        "contentType": "VIDEO",
        "title": "Coty, Gilead Sciences, Rent the Runway: Trending tickers",
        "description": "<p>Market Catalysts Host <a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/author/julie-hyman/\">Julie Hyman</a> recaps some of the trending tickers on Thursday, Aug. 21, including Coty (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/COTY\">COTY</a>), Gilead Sciences (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/GILD\">GILD</a>), and Rent the Runway (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/RENT\">RENT</a>).</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead Sciences (GILD), and Rent the Runway (RENT). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
        "pubDate": "2025-08-21T15:12:22Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-08/ca888a00-7e98-11f0-a37d-a7169c561e83",
          "originalWidth": 5000,
          "originalHeight": 2816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oAnqsexs.GX_eI.Z6mbFyg--~B/aD0yODE2O3c9NTAwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-08/ca888a00-7e98-11f0-a37d-a7169c561e83.cf.webp",
              "width": 5000,
              "height": 2816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TAc5IVcLMwbpoqr9g1owvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/ca888a00-7e98-11f0-a37d-a7169c561e83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/coty-gilead-sciences-rent-runway-151222727.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/coty-gilead-sciences-rent-runway-151222727.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "COTY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RENT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T14:17:47+00:00",
    "headline": "Stocks Pressured by Weak Walmart Earnings and Higher Bond Yields",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down by -0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.39%. September E-mini S&P futures (ESU25 ) are down -0.43%, and September...",
    "url": "https://www.barchart.com/story/news/34305424/stocks-pressured-by-weak-walmart-earnings-and-higher-bond-yields",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "fb1de1f1-f0fc-3f96-be30-b32a0c032e36",
      "content": {
        "id": "fb1de1f1-f0fc-3f96-be30-b32a0c032e36",
        "contentType": "STORY",
        "title": "Stocks Pressured by Weak Walmart Earnings and Higher Bond Yields",
        "description": "",
        "summary": "The S&P 500 Index ($SPX ) (SPY ) today is down by -0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.39%. September E-mini S&P futures (ESU25 ) are down -0.43%, and September...",
        "pubDate": "2025-08-21T14:17:47Z",
        "displayTime": "2025-08-21T14:17:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/d328f7db7fa019e809cef3d7281ab08b",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "Road sign of New York Wall street corner Broad street by Mezzotint via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gXiLaGUIp8AuUPsWJotxnw--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/d328f7db7fa019e809cef3d7281ab08b.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/84KGeqkyeGU_ADvBJZdOJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/d328f7db7fa019e809cef3d7281ab08b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/34305424/stocks-pressured-by-weak-walmart-earnings-and-higher-bond-yields",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-pressured-weak-walmart-earnings-141747287.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T13:21:08+00:00",
    "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
    "url": "https://finance.yahoo.com/news/market-chatter-cvs-health-won-132108276.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "ab4c78e5-ad38-3edc-b878-9b314143c6b8",
      "content": {
        "id": "ab4c78e5-ad38-3edc-b878-9b314143c6b8",
        "contentType": "STORY",
        "title": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
        "description": "",
        "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
        "pubDate": "2025-08-21T13:21:08Z",
        "displayTime": "2025-08-21T13:21:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-cvs-health-won-132108276.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-cvs-health-won-132108276.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "CI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T12:50:02+00:00",
    "headline": "Gilead stock falls after CVS holds off adding HIV prevention shot to plans",
    "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial plans for now.",
    "url": "https://finance.yahoo.com/news/gilead-stock-falls-cvs-holds-125002143.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "713545ec-c083-3a8f-b2e8-673d53ca5ca6",
      "content": {
        "id": "713545ec-c083-3a8f-b2e8-673d53ca5ca6",
        "contentType": "STORY",
        "title": "Gilead stock falls after CVS holds off adding HIV prevention shot to plans",
        "description": "",
        "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial plans for now.",
        "pubDate": "2025-08-21T12:50:02Z",
        "displayTime": "2025-08-21T12:50:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-stock-falls-cvs-holds-125002143.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-stock-falls-cvs-holds-125002143.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T12:30:00+00:00",
    "headline": "Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform",
    "summary": "SANTA MONICA, Calif. & PHILADELPHIA, August 21, 2025--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.",
    "url": "https://finance.yahoo.com/news/kite-acquire-interius-biotherapeutics-advance-123000111.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "296a786c-bcea-305c-990c-60734228f923",
      "content": {
        "id": "296a786c-bcea-305c-990c-60734228f923",
        "contentType": "STORY",
        "title": "Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform",
        "description": "",
        "summary": "SANTA MONICA, Calif. & PHILADELPHIA, August 21, 2025--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.",
        "pubDate": "2025-08-21T12:30:00Z",
        "displayTime": "2025-08-21T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/20cfd13fe31364b30d427e9407e6f72e",
          "originalWidth": 1595,
          "originalHeight": 480,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4Fz4mulN8wxO09o5HZX9jg--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/20cfd13fe31364b30d427e9407e6f72e.cf.webp",
              "width": 1595,
              "height": 480,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qjq08rfnY6fukL4P3RAiNQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/20cfd13fe31364b30d427e9407e6f72e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kite-acquire-interius-biotherapeutics-advance-123000111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kite-acquire-interius-biotherapeutics-advance-123000111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T11:57:00+00:00",
    "headline": "Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius",
    "summary": "The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.",
    "url": "https://www.biopharmadive.com/news/gilead-interius-acquire-in-vivo-cell-therapy/758266/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "54287b75-ec1a-3a2b-9fef-5e1af88c345b",
      "content": {
        "id": "54287b75-ec1a-3a2b-9fef-5e1af88c345b",
        "contentType": "STORY",
        "title": "Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius",
        "description": "",
        "summary": "The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.",
        "pubDate": "2025-08-21T11:57:00Z",
        "displayTime": "2025-08-21T11:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/552ec0fd71c517fb68fde1fde083c09a",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4ky82DL7VeM3XsV6P8DvHA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/552ec0fd71c517fb68fde1fde083c09a.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a8elOPH4xhnRAlMehDc15g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/552ec0fd71c517fb68fde1fde083c09a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/gilead-interius-acquire-in-vivo-cell-therapy/758266/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-dives-vivo-cell-therapy-115700818.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ACLX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-21T10:34:25+00:00",
    "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
    "url": "https://finance.yahoo.com/news/market-chatter-cvs-health-won-103425032.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "14c4862a-48a8-3dd6-85b6-d14012307158",
      "content": {
        "id": "14c4862a-48a8-3dd6-85b6-d14012307158",
        "contentType": "STORY",
        "title": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
        "description": "",
        "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
        "pubDate": "2025-08-21T10:34:25Z",
        "displayTime": "2025-08-21T10:34:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-cvs-health-won-103425032.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-cvs-health-won-103425032.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "CI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]